4.71
price up icon1.07%   0.05
after-market Dopo l'orario di chiusura: 4.85 0.14 +2.97%
loading

Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie

pulisher
Jul 22, 2025

What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vanda Pharmaceuticals Inc. a good long term investmentFree Trading Psychology Coaching - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Vanda Pharmaceuticals Inc. stockSignificant capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vanda Pharmaceuticals Inc. Stock Analysis and ForecastConsistently superior profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru

Jul 19, 2025
pulisher
Jul 17, 2025

Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks

Jul 17, 2025
pulisher
Jul 09, 2025

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com

Jul 09, 2025
pulisher
Jun 30, 2025

Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 17, 2025

Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360

Jun 13, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan

Jun 10, 2025
pulisher
Jun 09, 2025

Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow

Jun 09, 2025
pulisher
Jun 05, 2025

Vanda Approves Key Proposals at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire

Jun 03, 2025
pulisher
May 29, 2025

Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360

May 29, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire

May 27, 2025
pulisher
May 27, 2025

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow

May 27, 2025
pulisher
May 27, 2025

Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360

May 22, 2025
pulisher
May 22, 2025

Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow

May 21, 2025
pulisher
May 20, 2025

Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus

May 20, 2025
pulisher
May 19, 2025

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow

May 19, 2025
pulisher
May 18, 2025

Mystics enter new partnership with Vanda Pharmaceuticals - Monumental Sports Network

May 18, 2025
pulisher
May 17, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - The Malaysian Reserve

May 17, 2025
pulisher
May 16, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Mystics tap D.C.'s Vanda Pharmaceuticals as new jersey sponsor - The Business Journals

May 16, 2025
pulisher
May 16, 2025

Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports

May 16, 2025
pulisher
May 14, 2025

Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Can - GuruFocus

May 14, 2025
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Capitalizzazione:     |  Volume (24 ore):